Clinical trials: Myopia, Degenerative
Progressive Myopia
MAD Trial: Myopia Atropine Dose
The goal of this interventional study is to compare the efficacy of Atropine 0.05% to Atropine 0.5% treatment against progression of axial length in European children with progressive myopia, and to evaluate the safety…
- Trial name
- MAD (NCT05667454)
- Testing
- Atropine Ophthalmic 0.05%, Atropine Ophthalmic 0.5%
- Where
- 20 sites in Netherlands
- Volunteers
- 550 people
- Sponsor
- Erasmus Medical Center
Myopia, Progressive
Evaluation of the Safety and Efficacy of the D.D.C Dual-control Technology Spectacle Lenses in Delaying the Progression of Myopia: a Randomized Controlled Trial
The burden of myopia among Chinese children and adolescents is severe and trending toward younger ages, making control of myopia progression a public health priority.
- Trial name
- NCT07264361
- Testing
- D.D.C dual-control technology spcetacle lenses, Aspheric single-vision lenses
- Where
- China
- Volunteers
- 316 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Myopia Progression, Atropine
Efficacy and Safety of 0.01%, 0.03%, and 0.05% Atropine Eye Drops in Reducing Myopia Progression
Myopia is one of the fastest-growing ocular disorders worldwide and has become a major public health concern, especially among children and adolescents.
- Trial name
- NCT07626892
- Testing
- Atropine sulphate eye drop 0.01%, Atropine sulphate eye drop 0.03%, Atropine sulphate eye drop 0.05%
- Where
- Pakistan
- Volunteers
- 95 people
- Sponsor
- Khyber Medical College, Peshawar
Myopia, Progressive Myopia
Atropine Alone vs Atropine Plus Bifocal Spectacles for Myopia Control in Children
Background: Myopia (nearsightedness) is a growing global health concern, projected to affect 50% of the world population by 2050.
- Conditions
- Myopia, Progressive Myopia, Refractive Errors
- Trial name
- COMBAT-Myopia (NCT07614113)
- Testing
- Atropine Sulfate 0.05% Ophthalmic Solution, Bifocal Spectacles
- Where
- Pakistan
- Volunteers
- 210 people
- Sponsor
- University of Faisalabad
Myopia, Progressive
Choroidal Response to Novel Spectacle Lens to Control Myopia Progression
Diurnal variations in the thickness of the choroid have been reported in the literature, and, more recently, the role of the choroid has been studied with respect to its role in myopia (near-sightedness) progression.
- Trial name
- CHERRY (NCT03818880)
- Testing
- Novel spectacle lens design
- Where
- Canada
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- SightGlass Vision, Inc.
no Obvious Abnormalities, Diabetic Retinopathy (DR)
Retinal Clinical Assessment With AI-derived Quantitative Information
This randomized controlled trial evaluates whether providing clinicians with AI-derived quantitative retinal information improves the quality and efficiency of retinal clinical assessment.
- Conditions
- no Obvious Abnormalities, Diabetic Retinopathy (DR), AMD, Cup-to-disc Ratio Bigger Than 0.5
- Trial name
- NCT07291960
- Testing
- AI-derived retinal quantitative information-assisted reporting
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Beijing Tongren Hospital
Myopia, Progressive
Novel Lenses for Myopia Progression Trial
This is a multi-center , prospective, randomised, longitudinal study to evaluate rate of myopia progression with novel lenses compared to Single-Vision spectacles.
- Trial name
- NCT06563700
- Testing
- spectacle lens, single vision lens
- Where
- China
- Volunteers
- 342 people
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Progressive Myopia, Pediatric Myopia
Efficacy of Different Interventions for Progressive Myopia After Orthokeratology Lens Wear
Myopia has emerged as a significant concern impacting the visual health of children and adolescents on a global scale. According to research conducted by Holden BA et al., it is projected that by the year 2050, the worldwide…
- Conditions
- Progressive Myopia, Pediatric Myopia, Orthokeratology-related Myopia Progression
- Trial name
- NCT07494799
- Testing
- OK Lens Continuation Group, OK Lens + 0.01% Atropine Group, OK Lens with Reduced Optical Zone Group
- Volunteers
- 3,890 people
- Sponsor
- Tianjin Medical University Eye Hospital
Myopia, Progressive
Safety and Efficacy of Blue Star MAX-5 Lenses in Myopia Control
The goal of this randomised controlled clinical trial is to compare the effects of a new type of concentric columnar microstructure lens and single-vision spectacle lenses on myopia progression in Chinese children aged 8-11 years…
- Trial name
- NCT06647160
- Testing
- Blue star MAX-5 spectacle lens, Single-vision spectacle lens
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Myopia, Progressive
A Study of SHJ002 Sterile Ophthalmic Solution for Myopia Control
The objective of this study is to explore the safety and efficacy of SHJ002 Sterile Ophthalmic Solution relative to atropine in myopia control SHJ002 is an antisense oligonucleotide to neutralize a specific microRNA.
- Trial name
- NCT06579287
- Testing
- SHJ002, Atropine
- Where
- 9 sites in United States, Taiwan
- Volunteers
- 140 people
- Sponsor
- Sunhawk Vision Biotech, Inc.
Myopia, Myopia, Progressive
Multicenter RCT: LED Red Light Dose-Response in Myopia Progression Control
The goal of this clinical trial is to verify the effectiveness and safety of non-laser LED red light combined with defocus lens therapy for controlling myopia progression and evaluate the impact of different intervention…
- Trial name
- NCT07330180
- Testing
- Yingtong Vision Rehabilitation Instrument, Hoya DIMS multi-point myopia defocus lens
- Where
- 7 sites in China
- Volunteers
- 364 people, healthy volunteers welcome
- Sponsor
- Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Myopia, Progressive
Double Helix Design Defocus Lens Spectacle (RACE) for Myopia Control
This study uses 1.585 double helix defocus lens PC lenses with a unique optical design that includes a globally coherent visible area and complementary left and right helices that can form clear images.
- Trial name
- NCT05894382
- Testing
- Double Helix Design Defocus Lens Spectacle (RACE), single-vision spetacle lens
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Myopia, Progressive
Myopia Progression With Freeform Myopia Control Spectacles
This is a prospective, randomized clinical trial. There will be a total of 180 participants randomized into three groups, Group 1 - 60 participants will wear the commercial peripheral plus myopia control lens (CML).
- Trial name
- NCT06927388
- Testing
- freeform myopia control spectacles, Commercial myopia control spectacle lens (CML)
- Where
- China
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Shanghai Eye Disease Prevention and Treatment Center
Myopia, Progressive, Myopia
Clinical Evaluation of a Myopia Control Lens in Slowing Myopia Progression
This is a monocenter, randomized, controlled, parallel-group, double-masked clinical trial to evaluate the effectiveness of test lens in slowing myopia progression with respect to axial length elongation at baseline compared to a…
- Trial name
- NCT05331378
- Testing
- Test myopia control lenses, Single vision lenses
- Where
- Singapore
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Essilor International
Myopia, Progressive
Impact of Digital Screen Time in Progression of Myopia in Children
Research suggests that prolonged digital screen time is a significant contributing factor to the progression of myopia in children.
- Trial name
- NCT07055815
- Testing
- Progression of Myopia
- Where
- Pakistan
- Volunteers
- 79 people
- Sponsor
- Superior University
Retinal Diseases, Choroidal Disease
An Interpretable Fundus Diseases Report Generating System Based On Weakly Labelings
To establish a multimodal fundus image report generation model to realize an interpretable system for multiple fundus diseases, multimodal image analysis, diagnosis, and treatment decision automatic reporting based on weakly…
- Conditions
- Retinal Diseases, Choroidal Disease, Pathological Myopia, Diabetic Retinopathy
- Trial name
- NCT06918028
- Testing
- With fundus diseases, Without fundus diseases
- Where
- China
- Volunteers
- 9,999 people, healthy volunteers welcome
- Sponsor
- Zhongshan Ophthalmic Center, Sun Yat-sen University
Myopia, Myopia, Progressive
Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.
Phase III clinical study to evaluate the efficacy of Alleance® (atropine sulfate 0.01%) ophthalmic solution through the incidence of unexpected adverse events, changes in Best Corrected Visual Acuity (BCVA), changes in…
- Trial name
- NCT06389110
- Testing
- Alleance®
- Where
- Mexico
- Volunteers
- 123 people, healthy volunteers welcome
- Sponsor
- Laboratorios Sophia S.A de C.V.
Myopia, Progressive
Low-dose Atropine for Myopia Control in Children
Myopia (nearsightedness) is the most common eye disorder. Only second to age, it is the main risk factor for major degenerative eye diseases such as glaucoma, macular degeneration or retinal detachment.
- Trial name
- AIM (NCT03865160)
- Testing
- Atropine eye drops, 0.01%, Atropine eye drops, 0.02%
- Where
- 19 sites in Germany
- Volunteers
- 302 people
- Sponsor
- University Eye Hospital, Freiburg
Myopia, Myopia, Progressive
Kubota Glass Parameter Refinement Study
Length of the eye will be measured in subjects exposed to various stimulus characteristics using an electronic spectacle which presents illuminated targets to the eye.
- Conditions
- Myopia, Myopia, Progressive, Vision Disorders
- Trial name
- NCT06085430
- Testing
- Kubota Glass
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Kubota Vision Inc.
Myopia
Multicenter Evaluation of Near Vision and Outdoor Time in Kids Study
Currently, optical and pharmacological interventions have been developed to prevent the progression of childhood myopia. However, no myopia control strategy has been shown to have complete efficacy in controlling myopia…
- Trial name
- MENOK (NCT06119243)
- Testing
- Vivior
- Where
- 5 sites in United States, Australia
- Volunteers
- 230 people
- Sponsor
- The University of New South Wales